From September 6 to 9, 2025, Barcelona hosted the World Conference on Lung Cancer (WCLC 2025), one of the largest international gatherings dedicated to lung cancer research and patient care. Organized by the International Association for the Study of Lung Cancer (IASLC), the event brought together researchers, clinicians, and experts from around the world to share the latest scientific advances and strengthen the fight against thoracic cancers.
A must-attend global event in thoracic oncology
Every year, WCLC serves as a key platform to present cutting-edge research and discuss new therapeutic strategies. The 2025 edition highlighted significant progress in lung cancer management, particularly thanks to innovations in precision medicine and molecular biology.
Professor Paul Hofman highlights the key role of biomarkers
On this occasion, Professor Paul Hofman, Director of IHU RespirERA, spoke on September 6 in a session focused on the growing role of biomarkers in early-stage non-small cell lung cancer (NSCLC). Alongside Professors Sonja Loges and Sara Pilotto, he addressed several critical topics:
- Emerging treatment strategies for early-stage lung cancer
- The increasing importance of biomarker testing to better personalize therapies
- Challenges and solutions for integrating comprehensive biomarker testing into routine clinical practice
Biomarkers: paving the way for more precise and personalized medicine
Biomarkers are biological indicators that help better understand a tumor’s characteristics. In lung cancer, analyzing these markers is essential to tailor treatments to each patient, especially in the early stages of the disease. This approach improves treatment effectiveness and reduces the risk of relapse through precise and personalized monitoring.
IHU RespirERA: a key actor in personalized thoracic oncology
By participating in this international conference, Professor Hofman strengthened the visibility and expertise of IHU RespirERA in the field of personalized medicine in thoracic oncology. His contribution reflects the institute’s commitment to promoting innovative research and actively advancing clinical practices to provide patients with the most suitable treatments.
